LACRISERT

Compare LACRISERT  to:
Compare
Compare

Generic Name for LACRISERT

Hydroxypropyl cellulose 5mg; ocular insert; preservative-free.

Legal Classification:

Rx

Pharmacological Class for LACRISERT

Ocular lubricant.

Manufacturer of LACRISERT

Aton Pharma

Indications for LACRISERT

Moderate to severe dry eye syndromes.

Adult dose for LACRISERT

1 insert in each inferior cul-de-sac once or twice daily.

Children's dosing for LACRISERT

Not recommended.

Warnings/Precautions for LACRISERT

Instruct patients in insertion and removal. Do not rub eyes. Remove if persistent worsening of symptoms occurs.

Adverse Reactions for LACRISERT

Blurred vision, local irritation, photophobia, hyperemia.

How is LACRISERT supplied?

Inserts—60 (w. applicators)

Related Disease:

Dry eye~ocular lubricants

Related Resources

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

US Oftalmi recalls Camolyn eye drops and Fisiolin nasal drops

April 08, 2010

US Oftalmi has issued a nationwide voluntary recall of all its over-the-counter Camolyn eye drops and Fisiolin nasal drops in 15mL bottles due to conditions at the manufacturing facility that cannot assure the sterility of the products.

Phase 2 study of RX-10045 for the treatment of chronic dry eye syndrome

August 24, 2009

Resolvyx Pharmaceuticals announced positive data from its Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

Restasis available in 60-count package size

May 04, 2009

Restasis (cyclosporine 0.05%, from Allergan) ophthalmic emulsion is now available in a 60-count package (two trays of 30 vials) that provides patients with a 30-day supply.

Lacrisert now available from Aton

October 29, 2008

Aton Pharma has launched Lacrisert (hydroxypropyl cellulose ophthalmic insert) for the treatment of moderate-to-severe dry eye syndromes.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions